POMALYST is a prescription medicine, taken along with the medicine dexamethasone, used to treat adults with multiple myeloma who have previously received at least 2 medicines to treat multiple myeloma, including a proteasome inhibitor and lenalidomide, and whose disease has become worse during treatment or within 60 days of finishing the last treatment. It is not known if POMALYST is safe and effective in children.
How POMALYST works

POMALYST gives you multiple ways to fight multiple myeloma.
POMALYST has immune-modulating qualities similar to REVLIMID® (lenalidomide). However, POMALYST with dexamethasone is proven to continue the fight if multiple myeloma stops responding to REVLIMID and a proteasome inhibitor.
Taken in combination with dexamethasone, POMALYST
was shown to work in 3 ways in animal models and in vitro*:
STIMULATE
Helps enhance the function of certain cells used by the immune system to fight myeloma.
STRIKE
Targets and kills myeloma cells, even those resistant to REVLIMID.
STARVE
Helps reduce new myeloma cell growth by limiting blood supply.

WHY POMALYST?
If multiple myeloma stops responding to REVLIMID and a proteasome inhibitor (PI), POMALYST with dexamethasone may help:
- POMALYST with dexamethasone is proven to continue the fight after REVLIMID and a PI
- POMALYST has immune-modulating qualities similar to REVLIMID
- POMALYST is a once-daily* capsule, not an injection or infusion
*Taken on days 1-21 out of a 28-day cycle or as directed by your doctor.
A clinical trial proved POMALYST with dexamethasone was effective in patients with relapsed/refractory multiple myeloma.
Based on results of a clinical trial, the FDA has approved
the use of POMALYST with low-dose dexamethasone.
A clinical trial studied 455 patients whose multiple myeloma had stopped responding to at least 2 prior medicines, including REVLIMID (lenalidomide) and a PI. A total of 302 patients received POMALYST with low-dose dexamethasone, and 153 patients received high-dose dexamethasone alone.
Median overall survival was
1.5
TIMES
LONGER
The phase 3 clinical trial was designed to determine if POMALYST with low-dose dexamethasone could be an effective treatment for relapsed multiple myeloma.
MEDIAN OVERALL SURVIVAL (OS) RESULTS
Median Overall Survival (OS): Think of median as the middle value of a set of data points. Overall survival measures the amount of time patients were alive following the start of the trial.
Study findings: Median OS for patients taking POMALYST with low-dose dexamethasone was 12.4 months. This is roughly 1.5 times longer than the 8 months that patients lived when they were given high-dose dexamethasone alone.
Median progression-free survival was
2
TIMES
LONGER
MEDIAN PROGRESSION-FREE SURVIVAL (PFS) RESULTS
Median Progression-Free Survival (PFS): Progression-free survival (PFS) measures how long a patient lives without the disease getting worse. The main goal of the study was to measure median PFS.
Study findings: Median PFS for patients taking POMALYST with low-dose dexamethasone was 3.6 months. This was 2 times longer than the 1.8 months that patients lived without their disease getting worse when they were given high-dose dexamethasone alone.
POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.
Safety findings: Common side effects of POMALYST (≥30%) include low white blood cells, low red blood cells, tiredness and weakness, upper respiratory tract infection, low platelets, fever, shortness of breath, diarrhea, constipation, back pain, and nausea.
RRMM COMBINATION THERAPIES
POMALYST is used in the most FDA-approved combinations
for patients who have received prior treatments that included
REVLIMID® (lenalidomide) and a proteasome inhibitor.*
Your doctor may discuss these other treatment options with you and the associated risks and benefits. Please see the Combinations page to learn more about relapsed multiple myeloma treatment options.
*Please see full Prescribing Information, including Boxed WARNINGS, for REVLIMID.
LEARN MOREREFERENCE: Pomalidomide [package insert]. Summit, NJ: Celgene Corp; 2018.
POMALYST may not work for everyone. Ask your doctor if POMALYST with dexamethasone is right for you. Individual results may vary.
Before taking POMALYST, you need to join the POMALYST REMS® program.
LEARN MOREGet a comprehensive
guide to POMALYST with
the Treatment Overview
Brochure.
DownloadPOMALYST is a once-daily capsule.* See how to take it.
*POMALYST is taken once a day on days 1-21 of a 28-day cycle.
POMALYST is taken in combination with dexamethasone.